Literature DB >> 34053816

Quantifying the incidence of clinically significant respiratory depression in women with and without obesity class III receiving neuraxial morphine for post-cesarean analgesia: a retrospective cohort study.

H B Ende1, R L Dwan2, R E Freundlich3, S Dumas2, L L Sorabella2, B L Raymond2, M J Lozada2, M S Shotwell4, J P Wanderer3, J R Bauchat2.   

Abstract

BACKGROUND: Obesity is a suspected risk factor for respiratory depression following neuraxial morphine for post-cesarean analgesia, however monitoring guidelines for obese obstetric patients are based on small, limited studies. We tested the hypothesis that clinically significant respiratory depression following neuraxial morphine occurs more commonly in women with body mass index (BMI) ≥40 kg/m2 compared with BMI <40 kg/m2.
METHODS: We conducted a single-center, retrospective chart review (2006-2017) of obstetric patients with clinically significant respiratory depression following neuraxial morphine, defined as: (1) opioid antagonist administration; (2) rapid response team activation (initiated in April 2010); or (3) tracheal intubation due to a respiratory event. The incidence of respiratory depression was compared between women with BMI ≥40 kg/m2 and BMI <40 kg/m2.
RESULTS: In total, 11 327 women received neuraxial morphine (n=1945 BMI ≥40 kg/m2; n=9382 BMI <40 kg/m2). Women with BMI ≥40 kg/m2 had higher rates of sleep apnea, hypertensive disorders, and magnesium administration. Sixteen cases of clinically significant respiratory depression occurred within seven days postpartum. The incidence did not significantly differ between groups (odds ratio 2.2, 95% CI 0.6 to 6.9, P=0.174). Neuraxial morphine was not deemed causative in any case, however women with BMI ≥40 kg/m2 had higher rates of tracheal intubation unrelated to neuraxial morphine (2/1945 vs. 0/9382, P=0.029).
CONCLUSIONS: Respiratory depression in this population is rare. A larger sample (∼75 000) is required to determine whether the incidence is higher with BMI ≥40 kg/m2. Tracheal intubation was higher among the BMI ≥40 kg/m2 cohort, likely due to more comorbidities.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cesarean delivery; Neuraxial morphine; Obesity; Respiratory depression; Respiratory monitoring

Mesh:

Substances:

Year:  2021        PMID: 34053816      PMCID: PMC8314929          DOI: 10.1016/j.ijoa.2021.103187

Source DB:  PubMed          Journal:  Int J Obstet Anesth        ISSN: 0959-289X            Impact factor:   3.282


  16 in total

1.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  BMJ       Date:  2007-10-20

2.  Transcutaneous Carbon Dioxide Measurements in Women Receiving Intrathecal Morphine for Cesarean Delivery: A Prospective Observational Study.

Authors:  Jeanette R Bauchat; Robert McCarthy; Paul Fitzgerald; Stephen Kolb; Cynthia A Wong
Journal:  Anesth Analg       Date:  2017-03       Impact factor: 5.108

3.  A retrospective assessment of the incidence of respiratory depression after neuraxial morphine administration for postcesarean delivery analgesia.

Authors:  Theresa R Crowgey; Jennifer E Dominguez; Cathleen Peterson-Layne; Terrence K Allen; Holly A Muir; Ashraf S Habib
Journal:  Anesth Analg       Date:  2013-12       Impact factor: 5.108

4.  Postoperative opioid-induced respiratory depression: a closed claims analysis.

Authors:  Lorri A Lee; Robert A Caplan; Linda S Stephens; Karen L Posner; Gregory W Terman; Terri Voepel-Lewis; Karen B Domino
Journal:  Anesthesiology       Date:  2015-03       Impact factor: 7.892

5.  Society for Obstetric Anesthesia and Perinatology Consensus Statement: Monitoring Recommendations for Prevention and Detection of Respiratory Depression Associated With Administration of Neuraxial Morphine for Cesarean Delivery Analgesia.

Authors:  Jeanette R Bauchat; Carolyn F Weiniger; Pervez Sultan; Ashraf S Habib; Kazuo Ando; John J Kowalczyk; Rie Kato; Ronald B George; Craig M Palmer; Brendan Carvalho
Journal:  Anesth Analg       Date:  2019-08       Impact factor: 5.108

6.  Epidural morphine analgesia after cesarean delivery.

Authors:  D M Kotelko; P A Dailey; S M Shnider; M A Rosen; S C Hughes; R V Brizgys
Journal:  Obstet Gynecol       Date:  1984-03       Impact factor: 7.661

7.  Transcutaneous carbon dioxide levels and oxygen saturation following caesarean section performed under spinal anaesthesia with intrathecal opioids.

Authors:  S Dalchow; O Lubeigt; G Peters; A Harvey; T Duggan; A Binning
Journal:  Int J Obstet Anesth       Date:  2013-05-21       Impact factor: 2.603

8.  Delayed respiratory depression associated with 0.15 mg intrathecal morphine for cesarean section: a review of 1915 cases.

Authors:  Rie Kato; Hiroko Shimamoto; Katsuo Terui; Kazumi Yokota; Hideki Miyao
Journal:  J Anesth       Date:  2008-05-25       Impact factor: 2.078

9.  A Systematic Review Evaluating Neuraxial Morphine and Diamorphine-Associated Respiratory Depression After Cesarean Delivery.

Authors:  Nadir Sharawi; Brendan Carvalho; Ashraf S Habib; Lindsay Blake; Jill M Mhyre; Pervez Sultan
Journal:  Anesth Analg       Date:  2018-12       Impact factor: 5.108

10.  A prospective study of post-cesarean delivery hypoxia after spinal anesthesia with intrathecal morphine 150μg.

Authors:  Karim S Ladha; Rie Kato; Lawrence C Tsen; Brian T Bateman; Toshiyuki Okutomi
Journal:  Int J Obstet Anesth       Date:  2017-06-20       Impact factor: 2.603

View more
  2 in total

1.  The use of intrathecal morphine for acute postoperative pain in lower limb arthroplasty surgery: a survey of practice at an academic hospital.

Authors:  Mpumelelo Sibanyoni; Ntombiyethu Biyase; Palesa Motshabi Chakane
Journal:  J Orthop Surg Res       Date:  2022-06-21       Impact factor: 2.677

2.  Obstructive sleep apnea in pregnant women.

Authors:  Jennifer E Dominguez; Ashraf S Habib
Journal:  Int Anesthesiol Clin       Date:  2022-04-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.